Who Owns Zepbound?

Eli Lilly operates under a corporate sustainability framework that includes environmental targets, responsible sourcing, and ethical clinical trial practices. The company has committed to reducing Scope 1 and 2 greenhouse gas emissions by 40% by 2030 and achieving carbon neutrality by 2040.

The manufacturing expansion for tirzepatide products has raised questions about the environmental footprint of pharmaceutical production. Eli Lilly's new facilities incorporate energy-efficient designs and waste reduction systems. The company reports environmental performance data in its annual ESG report.

The more significant ethical questions around Zepbound involve pricing and access. At a list price of approximately $1,059.87 per month, Zepbound is unaffordable for many patients without insurance coverage. U.S. Medicare does not cover obesity medications, and many private insurance plans exclude or restrict coverage. Eli Lilly introduced the $399 vial format in 2024 to address affordability, but the vials are only available for the 2.5 mg and 5 mg doses and require self-administration with a syringe.

The SURMOUNT clinical trials followed standard ethical protocols, including informed consent, institutional review board oversight, and transparent reporting of results. Trial data was published in peer-reviewed journals including the New England Journal of Medicine and JAMA.

Eli Lilly has faced criticism for its marketing practices around Zepbound. The company has been accused of promoting the medication for cosmetic weight loss rather than medical necessity, though Eli Lilly states that its marketing is directed at healthcare providers and focuses on the approved indications.

• The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, demonstrated 22.5% average weight loss, the highest ever achieved in a pharmaceutical obesity trial.
• Zepbound received FDA approval in November 2023, approximately 18 months after Mounjaro's approval.
• In December 2024, Zepbound became the first FDA-approved prescription medication for obstructive sleep apnea in adults with obesity.
• Zepbound generated $4.97 billion in revenue in 2024, its first full year on the market, making it one of the fastest-growing pharmaceutical products in history.
• Combined tirzepatide revenue (Zepbound and Mounjaro) reached $16.4 billion in 2024, making tirzepatide one of the highest-grossing pharmaceutical franchises ever.

Supply shortages and compounded copies. From late 2023 through October 2024, Zepbound and Mounjaro experienced supply shortages due to demand exceeding manufacturing capacity. The FDA added tirzepatide to its shortage list, which allowed compounding pharmacies to produce copies. When the FDA removed tirzepatide from the shortage list in October 2024, compounding pharmacies were required to stop production. Eli Lilly filed lawsuits against several compounding pharmacies and telehealth companies that continued selling compounded tirzepatide. The company also launched the $399 vial format to provide a legitimate lower-cost alternative.

Pricing and access controversy. Zepbound's list price of approximately $1,059.87 per month has drawn criticism from patient advocacy groups, healthcare policy experts, and politicians. U.S. Medicare does not cover obesity medications under Part D, and many private insurance plans exclude or restrict coverage. Senator Bernie Sanders has publicly criticized Eli Lilly's pricing of Zepbound. Eli Lilly responds that the list price does not reflect the net price after rebates and discounts, and that the $399 vial format improves affordability. The company also offers a savings card for commercially insured patients that reduces out-of-pocket costs to as low as $25 per month.

Side effects and safety monitoring. Zepbound's label includes warnings for gastrointestinal side effects (nausea, vomiting, diarrhea, constipation), pancreatitis, gallbladder disease, and hypoglycemia when used with insulin. The FDA requires post-marketing surveillance for thyroid C-cell tumors based on animal studies, though this risk has not been confirmed in humans. Eli Lilly conducts ongoing safety monitoring through post-marketing studies and adverse event reporting.

Marketing practices. Eli Lilly has faced scrutiny over its marketing of Zepbound, particularly around direct-to-consumer advertising. Critics argue that the marketing promotes the medication for cosmetic weight loss rather than medical necessity. Eli Lilly states that its advertising is regulated by the FDA and focuses on the approved indications. The company has also faced criticism for marketing Zepbound through telehealth platforms that may prescribe the medication with limited patient evaluation.

Compounded tirzepatide safety concerns. During the shortage period, compounded tirzepatide products from compounding pharmacies and telehealth companies proliferated. Some of these products contained salt forms of tirzepatide (e.g., tirzepatide sodium) that have not been evaluated by the FDA for safety or efficacy. Eli Lilly warned that these non-identical copies could pose safety risks. The FDA issued warnings to compounding pharmacies about the use of non-standardized tirzepatide formulations.